Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ROS1 rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ROS1 rearrangement	Lung Cancer	ROS1 rearrangement	Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ROS1 rearrangement	Lung Adenocarcinoma	ROS1 rearrangement	Lung Adenocarcinoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ROS1 rearrangement	Lung Adenocarcinoma	ROS1 rearrangement	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	WX-0593 Sensitive: C3 – Early Trials WX-0593 Sensitive : C3	WX-0593 Sensitive: C3 – Early Trials WX-0593 Sensitive : C3
ROS1 rearrangement	Lung Adenocarcinoma	ROS1 rearrangement	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ROS1 rearrangement	Lung Adenocarcinoma	ROS1 rearrangement	Lung Adenocarcinoma	ceritinib Sensitive: C4 – Case Studies ceritinib Sensitive : C4	ceritinib Sensitive: C4 – Case Studies ceritinib Sensitive : C4
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	lorlatinib + verteporfin Sensitive: D – Preclinical lorlatinib + verteporfin Sensitive : D	lorlatinib + verteporfin Sensitive: D – Preclinical lorlatinib + verteporfin Sensitive : D